Recent evolution in co-pay assistance program designs, combined with policy developments around government-sponsored healthcare programs, has brought about a heightened focus on ensuring effective government exclusion and anti-kickback controls. As pharmaceutical manufacturers shift to alternate delivery and reimbursement models to address multiple payer tactics, it is imperative to maintain effective controls to prevent government-insured patients from accessing program benefits in accordance with the Federal Anti-Kickback Statute the Office of the Inspector General (OIG) guidance around coupon programs.
- Learn how to incorporate controls across multiple points in the patient’s interaction with your program to create layers of protection
- Discuss risks brought on by alternate program designs and how to mitigate them while still accomplishing program objectives
- Examine how recently-enacted policy developments and others being proposed could impact government exclusion and anti-kickback considerations going forward